Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663

British Journal of Pharmacology

Volumn 129, Issue 8, 2000, Pages 1748-1754

  Van Heek, Margaret ^a   Farley, Constance ^a   Compton, Douglas S ^a   Hoos, Lizbeth ^a   Alton, Kevin B ^a   Sybertz, Edmund J ^a,b   Davis Jr , Harry R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b GENZYME CORPORATION   (United States)

Author keywords

Cholesterol absorption; Enterohepatic circulation; Inhibition; Intestinal glucuronidation; Intestine; Plasma cholesterol

Indexed keywords

CHOLESTEROL; EZETIMIBE; GLUCURONIDE; HYPOCHOLESTEROLEMIC AGENT; SCH 60663; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BILE DUCT; CANNULATION; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENCY; GLUCURONIDATION; INTESTINE ABSORPTION; INTESTINE VILLUS; INTESTINE WALL; MALE; NONHUMAN; PORTAL VEIN BLOOD; PRIORITY JOURNAL; RAT; RHESUS MONKEY;

EID: 0034003105     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703235     Document Type: Article

References (21)

1. BACK, D.J. & ROGERS, S.M. (1987). Review: first-pass metabolism by the gastrointestinal mucosa. Aliment. Pharmacol. Ther., 5, 339-357.
2. BERGMAN, M., MORALES, H., MELLARS, L., KOSOGLOU, T., BURRIER, R., DAVIS, Jr. H.R., SYBERTZ, E.J. & POLLARE, T. (1995). The clinical development of a novel cholesterol absorption inhibitor, (abstract). XII International Symposium on Drugs Affecting Lipid Metabolism.
3. BURNETT, D.A., CAPLEN, M.A., DAVIS, H.R., BURRIER, R.E. & CLADER, J.W. (1994). 2-Azetidinones as inhibitors of cholesterol absorption. J. Med. Chem., 37, 1733-1736.
4. DAVIS, H.R., WATKINS, R.W., SALISBURY, B.G., COMPTON, D.S., SYBERTZ, E.J. & BURRIER, R.E. (1994). Effect of the cholesterol absorption inhibitor SCH48461 in combination with the HMG-CoA reductase inhibitor lovastatin in rabbits, dogs, and rhesus monkeys. Atherosclerosis, 109, 162.
5. DAVIS, H.R., VAN HEEK, M., WATKINS, R.W., ROSENBLUM, S.B., COMPTON, D.S., HOOS, L., MCGREGOR, D.G., PULA, K. & SYBERTZ, E.J. (1995). The hypocholesterolemic activity of the potent cholesterol absorption inhibitor SCH58235 alone and in combination with HMG CoA reductase inhibitors (abstract). XII International Symposium on Drugs Affecting Lipid Metabolism (DALM).
6. DAWSON, P.A. & RUDEL, L.L. (1999). Intestinal cholesterol absorption. Curr. Opin Lipidol, 10, 315-320.
7. FOLCH, J., LEES, M. & SLOAN-STANLEY, G.H. (1957). A simple method for isolation and purification of total lipids from animal tissues. J. Biol. Chem., 226, 497-509.
8. HAWK, C.T. & LEARY, S.L. (1995). In: Formulary for Laboratory Animals. American College of Laboratory Animal Medicine, p. 74.
9. IANNUCCI, R.M., KACZYNSKI, E.J., ACHANFUO-YEBOAH, J., ALVAREZ, M., BLUMENKRANTZ, N.B., CHOWDHURY, S.K., ALTON, K.B., PATRICK, J.E. & CAYEN, M.N. (1999). Metabolism of SCH58235 in the human, rat and dog (abstract). 47th American Society for Mass Spectrometry.
10. KRIETER, P.A., COLLETTI, A.E., MILLER, R.R. & STEARNS, R.A. (1995). Absorption and glucuronidation of the angiotensin II receptor antagonist losartan by the rat intestine. J. Pharm. Exp. Ther., 273, 816-822.
11. LIPID. (1998). The Long-Term Intervention with Pravastatin in Ischaemic Disease. (1998). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Eng. J. Med., 339, 1349-1357.
12. MILNE, R.W., NATION, R.L. & SOMOGYI, A.A. (1996). The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab. Rev., 28, 345-472.
13. NATIONAL RESEARCH COUNCIL Diet and Health, (1989). Implications for Reducing Chronic Disease Risk. National Academy Press, Washington, DC., pp. 529-547.
14. ROSENBLUM, S.B., HUYNH, T., AFONSO, A., DAVIS, H.R., YUMIBE, N., CLADER, J.W. & BURNETT, D.A. (1998). Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH58235): a designed, potent, orally active inhibitor of cholesterol absorption. J. Med. Chem., 41,973-980.
15. SACKS, F.M., PFEEFER, M.A., MOYE, L.A., ROULEAU, J.L., RUTHERFORD, J.D., COLE, T.G., BROWN, L., WARNICA, J.W., ARNOLD, J.M., WUN, C.C., DAVIS, B.R. & BRAUNWALD, E. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med., 335, 1001-1009.
16. SALISBURY, B.G., DAVIS, H.R., BURRIER, R.E., BURNETT, D.A., BOYKOW, G., CAPLEN, M.A., CLEMMONS. A.L., COMPTON, D.S., HOOS, L.M., MCGREGOR, D.G., SCHNITZER-POLOKOFF, R., SMITH, A.A., WEIG, B.C., ZILLI, D.L., CLADER, J. W & SYBERTZ, E.J. (1995). Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH48461. Atherosclerosis, 115, 45-63.
17. 4S. (1994). Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383-1389.
18. SHEPHERD, J., COBBE, S.M., FORD. I., ISLES, C.G., LORIMER. A.R., MACFARLANE, P.W., MCKILLOP, J.H. & PACKARD, C.J. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med., 333, 1301-1307.
19. SYBERTZ, E.J, DAVIS, H.R., VAN HEEK, M., BURRIER, R.E., SALISBURY, B.G., ROMANO, M.T., CLADER, J.W. & BURNETT, D.A. (1995). SCH48461, a novel inhibitor of cholesterol absorption. In: Atherosclerosis X. ed. Woodford, F.P., Davignon, J. & Sniderman, A. pp. 311-315. Pub. Elsevier.
20. VAN HEEK, M., FRANCE, C.F., COMPTON, D.S., MCLEOD, R.L., YUMIBE, N.P., ALTON, K.B., SYBERTZ, E.J. & DAVIS, H.R. (1997). In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J. Pharm. Exp. Ther., 283, 157-163.
21. ZBAIDA, S., SHANNON, D., DU, Y., NG, K., BLUMENKRANTZ, N., YUMIBE, N., PATRICK, J. & CAYEN, M. (1998). In vitro metabolism of SCH58235, 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone, by liver and kidney slices. (abstract). 12th International Symposium of Microsomes and Drug Oxidations, Montpellier, France.